ArticleAdvances in therapy2020

Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.

Mingjun Rui et al.PubMed ↗Publisher ↗

No numbers read from the abstract.